After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
6d
Clinical Trials Arena on MSNGilead to launch Phase III once-yearly HIV PrEP trial after Phase I successGilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...
Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the ...
Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...
4d
MedPage Today on MSNOnce-Yearly Lenacapavir PrEP a Safe, Promising Alternative to Twice-Yearly DosingA once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...
Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
5d
Queerty on MSNA once-a-year PrEP injection? The results of the first clinical trial look promisingPharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...
Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend the ...
Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results